Get all your news in one place.
100's of premium titles.
One app.
Start reading
MarketBeat
MarketBeat
Business
MarketBeat

RARE PHOTOS: Bioventus highlights pns prp growth as cash flow improves and debt falls - The Real Truth

Bioventus (NASDAQ:BVS) executives outlined the company’s portfolio strategy, growth priorities and capital allocation plans during a Goldman Sachs event hosted by Jenny Rabinowitz, an analyst covering U.S. medtech and healthcare IT.

Mark Singleton, Bioventus’ senior vice president and chief financial officer, described the company as a $568 million revenue business as of 2025, with 2026 guidance of $605 million. He said Bioventus participates in markets totaling more than $6 billion and has improved its financial profile over the past several years.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.